1 / 27

Immunogenicity of combined vaccines in infants

Immunogenicity of combined vaccines in infants. Helena Käyhty, PhD National Public Health Institute Dept of Vaccines Helsinki, Finland. Combined vs . reference administration hexavalent vaccines.

kareem
Download Presentation

Immunogenicity of combined vaccines in infants

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immunogenicity of combined vaccines in infants Helena Käyhty, PhD National Public Health Institute Dept of Vaccines Helsinki, Finland

  2. Combined vs. reference administrationhexavalent vaccines • Gylca et al. Vaccine 2001: DTaP-HBV-IPV / Hib vs. DTwP-IPV mixed with Hib +HBV at 6, 10, 14 weeks • Schmitt et al. J Ped 2000: mixed vs. separate DTaP-HBV-IPV / Hib at 2, 3, 4 months • Mallet et al. PIDJ 2000: DTaP-HBV-IPV-Hib vs. DTaP-IPV-Hib / HBV at 2, 4 and 6 months

  3. Combined vs. reference administration

  4. Eskola et al. Lancet 1996Vaccinations at 4 and 6 mo

  5. Three doses, combined vs. separate administration in different studies

  6. Mechanisms??? • Missing adjuvant effect of wP • Epitopic supression - antigenic competition • Physicochemical interference

  7. Immunogenicity trials in Sweden (3,5,12 mo) and Finland (4,6,14 mo)

  8. B B CHO Anti-CHO Ab T HELP Anti-Tetanus Ab Tet B B

  9. B Anti-CHO Ab HELP Anti-Tetanus Ab

  10. PncT, PRP-T and T simultaneouslyDose of PncT and response to PRP-T and Tetanus toxoid (Dagan et al. 1998)

  11. Concomitant administration 2 cm apart in the same leg at 2, 4 and 6 moEskola et al.

  12. Clinical implications? • Are the induced anti-Hib responses high enough for protection? • Experience from Finland, Sweden, the UK and Germany

  13. Protective efficacy vs. antibody response

  14. Protective efficacy vs. antibody response

  15. Immunogenicity trials in Sweden (3,5,12 mo) and Finland (4,6,14 mo)

  16. Three doses, combined vs. separate administration in different studies

  17. DTaP/Hib/(IPV) combinations in Germany Schmitt et al 2001 • 2 year follow up after the introduction of combined vaccines • Overall VE 97.5 % (96.3-98.4) • 1 dose 88.6 % (76.1-94.3) • 2 doses 95.1 % (92.2-97.0) • 3 doses 98.8 % (98.2-99.3)

  18. Measurement of the immune response to vaccination Vaccine  Sample Antibody

  19. Capsular polysaccharides (PS) • Antibodies protective • Poor and short lasting immune response in infants and children • Long lasting antibody response in older children and adults • TI-antigens -> no memory -> protection is based on existing antibodies

  20. Conjugate vaccines???? • immunogenicity improved by conjugating PS to carrier proteins -> TD properties -> antibody response even in infancy • development of memory • protection may last longer than detectable antibody • memory B cells triggered upon challenge -> high and quick antibody response • increase in avidity -> antibodies may function better

  21. How to test development of memory • Memory B cells • Priming with conjugate and booster with PS • PS mimics contact with bacteria • more memory B cells to be triggered by PS • high antibody response of IgG isotype • Avidity maturation

  22. Increasing Affinity / Avidity 104 108 1012

  23. 1.0 0.9 100.0 0.8 0.7 0.6 10.0 0.5 0.4 0.3 1.0 0.2 0.1 0.0 0.1 4 6 8 10 12 14 0 2 Geometric mean titer (GMT) and GM avidity index (GMAI) Avidity Titre Anti-PRP Igg (GMT µg/ml) Avidity Index (GMAI) Age (months) Goldblatt et al., JID 177, 1998, 1112-5

  24. Poolman et al Vaccine 2001

  25. Avidity of anti-6B Pnc PS-primary seria at 2,4,6 mo with a conjugate - booster at 14 mo with conjugate or PS

  26. Laboratory surrogates for evaluation of new conjugates, modified from Frasch 1995 • antibody response in infancy • persistence of antibodies (up to booster dose) • induction of immunologic memory • PS-vaccine • avidity • isotype/subclass distribution and avidity of antibodies • functional activity of antibodies (opsonic or bactericidal activity)

  27. Mucosal immune response • is or may be important when • local mucosal infection • colonization precedes disease • the role as a surrogate test unknown

More Related